Novartis, Mariana Oncology
Novartis to Buy Mariana Oncology, Paying $1 Billion Upfront
Novartis agreed to buy US biotech Mariana Oncology Inc. to strengthen its pipeline of drugs that can specifically target cancer cells.
Novartis to buy radiology drug specialist Mariana for $1 billion
Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday.
Novartis bolsters radioligand portfolio with $1bn Mariana buy
Novartis will acquire Mariana Oncology, a Watertown, Massachusetts-based biotech company dealing in radioligand therapies (RLTs) to treat cancer.
Novartis to pay $1B upfront for Watertown startup aiming to improve radiation treatment
Novartis is shelling out $1 billion upfront to buy a Watertown startup that's working to make radiation treatment more precise for small cell lung and other types of cancers.
Novartis further entrenches into radiopharma with $1B Mariana buy
With much still to discover in the massive world of radiopharmaceuticals, Novartis will take a deep dive into the unknown with Mariana Oncology in a $1 billion upfront acquisition. | With much still to discover in the massive world of radiopharmaceuticals,
Novartis to buy Mariana Oncology for $1B upfront
Novartis (NYSE:NVS) has agreed to acquire cancer drugmaker Mariana Oncology for an upfront payment of $1B and an additional $750M in milestone payments. The transaction, subject to customary closing conditions,
Novartis to Buy Mariana Oncology for Up to $1.75 Bln in Boost to Radioligand Therapy Business
By Mauro Orru Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand
FiercePharma7h
Entresto puts Novartis at top of docs' ranking of heart disease drug makers, with Pfizer close behind
In an ongoing battle for dominance in the eyes of healthcare professionals for their work developing heart disease-focused drugs, Novartis has now snatched the top spot from Pfizer, according to a ...
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.
STAT5d
Novartis extends radiopharma plans with $1 billion acquisition
Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these ...
FierceBiotech8d
Novartis pays PeptiDream $180M as radiopharma big bang continues
Novartis is pumping another $180 million into its radioligand plan, handing the cash to serial dealmaker PeptiDream to ...
GEN6d
Novartis to Acquire Mariana for Up to $1.75B, Expanding Radiopharma Pipeline
Novartis has agreed to acquire Mariana Oncology for up to $1.75 billion, the companies said today, in a deal that would ...
STAT6d
Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama
Also on this week’s episode, we discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo ...
Canadian HR Reporter1d
AI closeup: Ashley Sardjoe of Novartis details how ChatGPT elevates company’s HR work
Canadian HR Reporter recently spoke with Novartis Canada’s Global People and Organization Leader, Ashley Sardjoe, about how ...